A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2015
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid abuse
- Focus Adverse reactions
- Sponsors Orexo
- 22 Apr 2015 Results published in an Orexo media release.
- 22 Apr 2015 Status changed from active, no longer recruiting to completed, based on an Orexo media release.
- 27 Nov 2014 New trial record